Quantum-Si incorporated

NASDAQ:QSI

Biotechnology

Healthcare
$1.07 +5.02%

+$0.05 today

Market cap
$213.79M
Beta
3.17
P/E (TTM)
-2.1
EPS (TTM)
-$0.48
52W Low $0.69High $3.10

Volume 10.47M

Average 5.64M

QSI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Quantum-Si incorporatedNASDAQ: QSI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $2.57M rose 8.6% year over year, behind the +14.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.

Context

  • Stock-based compensation amounted to 442.2% of revenue in FY2025, up 151.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +8.6% toward the trailing-twelve-month pace of +14.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.57M-4.6% QoQ
Last fiscal yearDec 2025
$10.77M+21.2% YoY
LTMMar 2026
$10.98M+14.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.6%——
1 year+21.2%——
3-year CAGR-1.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.77M USD
Year-over-year change
+21.2%
4-year CAGR
-18.9%

Stock-Based Compensation vs competitors

How QSI compares with its peers on the latest reported figures

  • QSI's LTM Mar 2026 stock-based compensation of $10.98M is the 9th largest of the 11 companies compared; the peer median is $14.88M.
  • Its year-over-year change of +14.3% is the 6th highest of 10, against a peer median of +18.7%.
  • Stock-based compensation amounts to 592.7% of revenue for QSI, versus a peer median of 16.3%.
QSI Competitors Peer median
Stock-Based Compensation for QSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
SLDBSolid Biosciences Inc.LTM Mar 2026$18.73M +52.9%+30.9%—
ANNXAnnexon, Inc.LTM Mar 2026$15.5M -21.9%-3.9%—
ALTAltimmune, Inc.LTM Mar 2026$15.44M +4.6%+25.7%42886.1%
AUTLAutolus Therapeutics plcLTM Mar 2026$15.14M -5.7%+6.3%16.3%
AURAAura Biosciences, Inc.LTM Mar 2026$14.63M +18.7%+30.7%—
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
ENGNenGene Holdings Inc.LTM Apr 2026$12.14M +60.2%+336.5%—
QSIQuantum-Si incorporatedLTM Mar 2026$10.98M +14.3%-1.3%592.7%
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M +37.2%+2.3%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$1.37M ———
Peer median (excluding QSI) $14.88M+18.7%+6.3%16.3%

Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(94.99M)(132.44M)(95.96M)(101.01M)(101.34M)
Depreciation & Amortization1.04M2.58M4.16M4.6M4.45M
Deferred Income Tax714K0000
Stock-Based Compensation24.92M11.21M8.52M8.89M10.77M
Change in Working Capital1.47M3.05M(3.2M)4.64M(4.58M)
Accounts Receivables00(368K)(1.09M)626K
Inventory00286K4.34M(2.01M)
Accounts Payables709K721K(1.22M)390K(338K)
Other Working Capital758K2.33M(1.89M)1M(2.86M)
Other Non-Cash Items36K25.04M(7.55M)(4.92M)(4.03M)
Operating Cash Flow(66.81M)(90.56M)(94.04M)(87.8M)(94.72M)
Capital Expenditures(5.76M)(10.74M)(5.27M)(4.58M)(2.52M)
Acquisitions (Net)(4.63M)0000
Purchases of Investments(440.54M)(834K)(123.81M)(369.43M)(404.58M)
Sales of Investments445.17M148.76M272.51M341.4M378.78M
Other Investing Activities(445.17M)0(763K)(59K)0
Investing Cash Flow(450.94M)137.19M143.43M(32.68M)(28.32M)
Debt Repayment(1.78M)0000
Common Stock Issued512.79M2.76M034.79M95.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.61M(848K)149K1.09M1K
Financing Cash Flow516.63M1.91M149K35.88M95.42M
Effect of Forex Changes000(25K)12K
Net Change in Cash(1.13M)48.53M49.54M(84.62M)(27.6M)
Free Cash Flow(72.58M)(101.3M)(99.31M)(92.38M)(97.23M)

Quantum-Si incorporated

NASDAQ:QSI

Intrinsic Alpha fair value

Locked

Current Price

$1.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.